Evidence map›Paper›PMID 35033105›Full record

ArticleRetrovirology2022

Reduced and highly diverse peripheral HIV-1 reservoir in virally suppressed patients infected with non-B HIV-1 strains in Uganda.

Samira Joussef-Piña, Immaculate Nankya, Sophie Nalukwago, Joy Baseke, Sandra Rwambuya, Dane Winner, Fred Kyeyune, Keith Chervenak, Bonnie Thiel, Robert Asaad and 7 more

Abstract read
In one paragraph

Article in Retrovirology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Samira Joussef-PiñaDepartments of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH, USA.
Immaculate NankyaCenter for AIDS Research Uganda Laboratories, Joint Clinical Research Centre, Kampala, Uganda.
Sophie NalukwagoCenter for AIDS Research Uganda Laboratories, Joint Clinical Research Centre, Kampala, Uganda.
Joy BasekeCenter for AIDS Research Uganda Laboratories, Joint Clinical Research Centre, Kampala, Uganda.
Sandra RwambuyaCenter for AIDS Research Uganda Laboratories, Joint Clinical Research Centre, Kampala, Uganda.
Dane WinnerDepartments of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH, USA.
Fred KyeyuneCenter for AIDS Research Uganda Laboratories, Joint Clinical Research Centre, Kampala, Uganda.
Keith ChervenakDepartments of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Bonnie ThielDepartments of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Robert AsaadDepartments of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Curtis DobrowolskiDepartments of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH, USA.
Benjamin LuttgeDepartments of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH, USA.
Blair LawleyDepartment of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, 720 Cumberland Street, P.O. Box 56, Dunedin, New Zealand.
Cissy M KityoCenter for AIDS Research Uganda Laboratories, Joint Clinical Research Centre, Kampala, Uganda.
W Henry BoomCenter for AIDS Research Uganda Laboratories, Joint Clinical Research Centre, Kampala, Uganda.
Jonathan KarnDepartments of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH, USA.
Miguel E Quiñones-MateuCenter for AIDS Research Uganda Laboratories, Joint Clinical Research Centre, Kampala, Uganda. miguel.quinones-mateu@otago.ac.nz.ORCID 0000-0001-9170-5601

Funding

WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Sharon L. Hillier, JONATHAN KARN · 1994 to 2026
$50.0M
Gene editing strategies to target HIV for elimination in periphery and brainR01MH110360 · NIMH · DREXEL UNIVERSITY · PI Ilker Kudret Sariyer, Brian Wigdahl · 2016 to 2026
$7.3M
Identification and eliminationof HIV reservoirs in oral lymphoid tissues by engineered NK cells.R01DE025464 · NIDCR · CASE WESTERN RESERVE UNIVERSITY · PI KARN, JONATHAN · 2015 to 2019
$3.8M
Impact of Non - B HIV - 1 Subtype on second line Protease Inhibitor Regimens in Africa (INSPIRE)R01AI147331 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI CHARURAT, MANHATTAN E, NDEMBI, NICAISE · 2020 to 2025
$2.9M
Control of P-TEFb biogenesis and HIV transcription in primary T-cellsR01AI148083 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI KARN, JONATHAN, MBONYE, URI · 2019 to 2023
$2.0M
NIAID NIH HHS P30 AI036219NIAID NIH HHS R01 AI147331NIAID NIH HHS R01 AI148083NIDCR NIH HHS R01 DE025464NIH HHS R01 MH1103601NIMH NIH HHS R01 MH110360
6 · The paper itself

Abstract

backgroundOur understanding of the peripheral human immunodeficiency virus type 1 (HIV-1) reservoir is strongly biased towards subtype B HIV-1 strains, with only limited information available from patients infected with non-B HIV-1 subtypes, which are the predominant viruses seen in low- and middle-income countries (LMIC) in Africa and Asia.

resultsIn this study, blood samples were obtained from well-suppressed ART-experienced HIV-1 patients monitored in Uganda (n = 62) or the U.S. (n = 50), with plasma HIV-1 loads < 50 copies/ml and CD4

conclusionsThe smaller, but more diverse, peripheral HIV-1 reservoir in Ugandan patients might be associated with viral (e.g., non-B subtype with higher cytopathicity) and/or host (e.g., higher incidence of co-infections or co-morbidities leading to less clonal expansion) factors. This highlights the need to understand reservoir dynamics in diverse populations as part of ongoing efforts to find a functional cure for HIV-1 infection in LMICs.

Indexed as

HIV-1HIV InfectionsAdultAnti-Retroviral AgentsCD4-Positive T-LymphocytesHumansProvirusesUgandaViral LoadAnti-Retroviral AgentsCo-infectionHIVReservoirSubtypeUganda

Identifiers

PMID35033105
PMCPMC8760765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.